Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
John Lee Welborn Insider Profile
4 Followers
John Lee Welborn, Director at HLS Therapeutics Inc, holds 97.00K shares in HLS Therapeutics Inc (Ticker: TSE:HLS). Most recently, John Lee Welborn Bought C$97,000 shares of HLS Therapeutics Inc on Jun 13, 2023 for an estimated value of 417.10K.
John Lee Welborn has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
100.00%
A breakdown of John Lee Welborn's holdings
Insider Roles
Director
Roles that John Lee Welborn holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by John Lee Welborn
John Lee Welborn's Trading History
List of latest transactions for each holding click on a transaction to see John Lee Welborn's performance on stock
You May Also Like
John Lee Welborn insider profile FAQ
What is the percentage of profitable transactions made by John Lee Welborn?
The percentage of profitable transactions made by John Lee Welborn is ―.
What is the average return per transaction made by John Lee Welborn?
The average return per transaction made by John Lee Welborn is ―.
What stocks does John Lee Welborn hold?
John Lee Welborn holds: TSE:HLS stocks.
What was John Lee Welborn’s latest transaction?
John Lee Welborn latest transaction was an Informative Buy of C$417.10K.
What was John Lee Welborn's most profitable transaction?
John Lee Welborn’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is John Lee Welborn's role in HLS Therapeutics Inc?
John Lee Welborn's role in HLS Therapeutics Inc is Director.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.